Foundation Medicine GeneKit
Foundation Medicine has introduced GeneKit, a genomics solutions portal for pathologists. Powered by FoundationCORE, the company's knowledgebase of comprehensive genomic cancer information, GeneKit facilitates the interpretation of genomic data generated by pathologists from targeted next-generation sequencing and "hot spot" assays, the company said. This integration is designed to help pathologists more effectively support clinical diagnosis and treatment strategies via the rapid interpretation and efficient reporting of genomic information to oncology care teams, the company noted.
AltheaDx Oncology Panel 150
AltheaDx has received CLIA validation for a next-generation sequencing panel for its pharma services program. The AltheaDx Oncology Panel 150 (AOP 150) is a targeted, NGS assay for drug and companion diagnostic development programs, and simultaneously tests 143 solid tumor genes. The panel is based on Thermo Fisher Scientific's Oncomine Comprehensive Assay and runs on the Ion Torrent NGS platform. It s designed to work with minimal sample input per run and is well-suited for analysis of tumor samples extracted from formalin-fixed paraffin-embedded tissue, including small biopsies and fine needle aspirates, AltheaDx said.
Lexogen's Spike-in RNA Variant Control Mixes
Lexogen has launched Spike-in RNA Variant Control Mixes for the quantification of mRNA isoforms in next-generation sequencing. The firm said the SIRVs are a set of 69 artificial transcript variants that mimic 7 human model genes, and they are the only RNA control designed specifically for splice variant detection. According to Lexogen, the SIRVs can be analyzed with any RNA-Seq protocol starting from cell extracts or purified RNA and on any NGS platform, including those from Illumina, Life Technologies, and Pacific Biosciences.
For more recent product launches please visit the New Products page on our website.